A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers.
M-27312-01
Phase 1 other active
Quick answer
A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers. for Inflammatory diseases is a Phase 1 program (other) at Almirall with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Almirall
- Indication
- Inflammatory diseases
- Phase
- Phase 1
- Modality
- other
- Status
- active